About Adam Koppel
Adam Koppel is a director and 10% owner at Kailera Therapeutics.
Form D filings name Adam Koppel as a director at Cardurion Pharmaceuticals.
Adam Koppel reports to the SEC as a director, officer or major shareholder of 16 public companies, including Foghorn Therapeutics (FHTX), Cerevel Therapeutics (CERE) and Solid Biosciences (SLDB).
Adam Koppel first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Adam Koppel in the role, so the role may have started earlier or lasted longer.
KI
Kailera Therapeutics, Inc.
Director and 10% owner
2026 · Public company (KLRA)
FI
Foghorn Therapeutics Inc.
Director
2020 – 2024 · Public company (FHTX)
CI
Cerevel Therapeutics Holdings, Inc.
Director and 10% owner
2020 – 2024 · Public company (CERE)
SI
Solid Biosciences Inc.
Director and 10% owner
2018 – 2024 · Public company (SLDB)
AI
Aptinyx Inc.
Director and 10% owner
2018 – 2022 · Public company (APTX)
DI
Dicerna Pharmaceuticals Inc
Director and 10% owner
2017 – 2021 · Public company (DRNA)
SI
SpringWorks Therapeutics, Inc.
10% owner
2019 – 2021 · Public company (SWTX)
RI
Rapid Micro Biosystems, Inc.
10% owner
2021 · Public company (RPID)
BC
BCLS Acquisition Corp.
Director and 10% owner
2020 · Public company (BLSA)
AI
Annexon, Inc.
10% owner
2020 · Public company (ANNX)
AI
Arcutis Biotherapeutics, Inc.
10% owner
2020 · Public company (ARQT)
RI
Replimune Group, Inc.
Director and 10% owner
2018 · Public company (REPL)
TI
Trevena Inc.
Director
2014 – 2018 · Public company (TRVN)
MI
Marinus Pharmaceuticals, Inc.
10% owner
2017 · Public company (MRNS)
PI
PTC Therapeutics, Inc.
Director
2013 – 2017 · Public company (PTCT)
BI
Biogen Inc.
EVP, Strategy and Bus. Dev
2014 – 2016 · Public company (BIIB)
Key Colleagues at Startups
The people Adam Koppel works with at each company, as listed on that company's latest Form D.
Cardurion Pharmaceuticals, Inc. · Form D, Jul 24, 2024
ER
Evan Rachlin
Director
Jeb Keiper
Director
MM
Michael Mendelsohn
Executive officer and director
DL
Daniel Lynch
Director
ER
Emma Reeve
Director
PL
Peter Lawrence
President and Chief Executive Officer, director
EM
Edward Mathers
Director
ND
Nicholas Downing
Director